Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
D001706:Biopsy; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014642:Vanilmandelic Acid / Q000134:cerebrospinal fluid; D014839:Vomiting / Q000139:chemically induced
D004338:Drug Combinations; D006897:Hydroxyindoleacetic Acid; D014642:Vanilmandelic Acid; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases